1. Home
  2. RMCO vs VERU Comparison

RMCO vs VERU Comparison

Compare RMCO & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Management Holding Corporation

RMCO

Royalty Management Holding Corporation

HOLD

Current Price

$2.79

Market Cap

35.0M

Sector

Miscellaneous

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.33

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCO
VERU
Founded
2021
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.0M
40.9M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
RMCO
VERU
Price
$2.79
$2.33
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
31.3K
49.5K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
0.36%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
$209.10
N/A
Revenue Next Year
$133.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.98
$0.36
52 Week High
$5.00
$4.59

Technical Indicators

Market Signals
Indicator
RMCO
VERU
Relative Strength Index (RSI) 43.85 47.52
Support Level $2.80 $2.13
Resistance Level $3.82 $2.67
Average True Range (ATR) 0.27 0.11
MACD 0.05 -0.00
Stochastic Oscillator 54.24 21.82

Price Performance

Historical Comparison
RMCO
VERU

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: